☆ 4.8 Article

Prime-Boost Vaccination With Covaxin/BBV152 Induces Heightened Systemic Cytokine and Chemokine Responses

FRONTIERS IN IMMUNOLOGY (2021)

Related references

Note: Only part of the references are listed.

Review Biochemistry & Molecular Biology

COVID-19 vaccines: where we stand and challenges ahead

Guido Forni et al.

Summary: The development of vaccines has made significant progress, but still faces various challenges, including different target populations, immunological adaptability of vaccines, and production and distribution issues. To ensure equitable access, protection of diverse subjects, and immunity against viral variants, multiple vaccines may be needed in the long run.

CELL DEATH AND DIFFERENTIATION (2021)

Add to Collection

Article Infectious Diseases

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Raches Ella et al.

Summary: The BBV152 vaccine demonstrated tolerable safety outcomes and enhanced immune responses in this clinical trial, leading to selection of both Algel-IMDG formulations for phase 2 immunogenicity trials. Further efficacy trials are warranted to validate the vaccine's effectiveness.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Chemokines and chemokine receptors during COVID-19 infection

Bariaa A. Khalil et al.

Summary: Chemokines play a crucial role in the immune response by clearing pathogens, but their excessive release can lead to hyperinflammation and severe complications. In COVID-19, chemokines may directly cause acute respiratory distress syndrome, increasing the risk of death. Understanding the role of chemokines in COVID-19 pathogenesis is important for developing potential therapeutic targets.

COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2021)

Add to Collection

Article Infectious Diseases

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Raches Ella et al.

Summary: BBV152 vaccine, consisting of whole-virion inactivated SARS-CoV-2 with Algel and IMDG, showed high neutralizing antibody responses in phase 1 trial and better reactogenicity in phase 2 trial. The 6 mu g with Algel-IMDG formulation has been chosen for phase 3 efficacy trial.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Multidisciplinary Sciences

Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques

Pragya D. Yadav et al.

Summary: This study demonstrates the protective efficacy and immunogenicity of the inactivated SARS-CoV-2 vaccine BBV152 in rhesus macaques, indicating that the vaccine candidate is in clinical development.

NATURE COMMUNICATIONS (2021)

Add to Collection

Review Immunology

SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates

Nikolaos C. Kyriakidis et al.

Summary: The new SARS-CoV-2 virus is rapidly spreading worldwide, causing the COVID-19 pandemic with more than 1.866 million deaths. Over 64 vaccine candidates are being developed globally, aiming to induce antibodies to prevent viral entry. Thirteen vaccine candidates are currently in Phase 3 clinical trials, showing promising progress towards approval for large-scale immunizations.

NPJ VACCINES (2021)

Add to Collection

Article Multidisciplinary Sciences

Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation

Brunda Ganneru et al.

Summary: The study reports the development and evaluation of a whole virion inactivated COVID-19 vaccine, showing high antigen-binding and neutralizing antibody titers in mice, rats, and rabbits, with excellent safety profiles.

ISCIENCE (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Heterologous vaccine interventions: boosting immunity against future pandemics

Daniela Marin-Hernandez et al.

Summary: Traditional vaccines are designed to target specific pathogens, but there are known off-target effects that can impact unrelated pathogen infections. Heterologous vaccines, like BCG, can induce non-specific effects through trained immunity.

MOLECULAR MEDICINE (2021)

Add to Collection

Article Medicine, Research & Experimental

Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection

Natalia Sherina et al.

Summary: The study shows that 85% of samples from COVID-19 patients had anti-SARS-CoV-2 antibodies within 4 weeks of symptom onset, while specific IgG antibodies and plasma neutralizing activities remained relatively stable up to 6 months after diagnosis. 80% of samples collected at 6-8 months after symptom onset still had anti-SARS-CoV-2 IgG antibodies, and specific memory B and T cell responses continued to develop and persist.

MED (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection

Mihai G. Netea et al.

CELL (2020)

Add to Collection

Review Biochemistry & Molecular Biology

SARS-CoV-2 infection: The role of cytokines in COVID-19 disease

Victor J. Costela-Ruiz et al.

CYTOKINE & GROWTH FACTOR REVIEWS (2020)

Add to Collection

Article Microbiology

BCG Vaccination in Humans Elicits Trained Immunity via the Hematopoietic Progenitor Compartment

Branko Cirovic et al.

CELL HOST & MICROBE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Activate: Randomized Clinical Trial of BCG Vaccination against Infection in the Elderly

Evangelos J. Giamarellos-Bourboulis et al.

CELL (2020)

Add to Collection

Review Immunology

Vaccines for COVID-19

J. S. Tregoning et al.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Ugur Sahin et al.

NATURE (2020)

Add to Collection

Article Medicine, General & Internal

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

E. J. Anderson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Medicine, General & Internal

Cytokine Storm

David C. Fajgenbaum et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, Research & Experimental

Peripheral CD4+ T cell subsets and antibody response in COVID-19 convalescent individuals

Fang Gong et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2

Michele Catanzaro et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)

Add to Collection

Review Immunology

Defining trained immunity and its role in health and disease

Mihai G. Netea et al.

NATURE REVIEWS IMMUNOLOGY (2020)

Add to Collection

Article Cell Biology

The immunomodulatory effects of measles-mumps-rubella vaccination on persistence of heterologous vaccine responses

Petra Zimmermann et al.

IMMUNOLOGY AND CELL BIOLOGY (2019)

Add to Collection

Editorial Material Microbiology

The Role of Interleukin 6 During Viral Infections

Lauro Velazquez-Salinas et al.

FRONTIERS IN MICROBIOLOGY (2019)

Add to Collection

Article Immunology

Maternal BCG scar is associated with increased infant proinflammatory immune responses

Patrice Akusa Mawa et al.

VACCINE (2017)

Add to Collection

Review Biochemistry & Molecular Biology

Cytokines and persistent viral infections

Jean-Christophe Beltra et al.

CYTOKINE (2016)

Add to Collection

Review Public, Environmental & Occupational Health

Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs

Nikolai Petrovsky

DRUG SAFETY (2015)

Add to Collection

Review Biochemistry & Molecular Biology

Key roles of adjuvants in modern vaccines

Steven G. Reed et al.

NATURE MEDICINE (2013)

Add to Collection

Article Allergy

Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways

Victoria J. Philbin et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)

Add to Collection

Article Multidisciplinary Sciences

Potent Adjuvanticity of a Pure TLR7-Agonistic Imidazoquinoline Dendrimer

Nikunj M. Shukla et al.

PLOS ONE (2012)

Add to Collection

Review Immunology

Modulation of chemokine activity by viruses

Antonio Alcami et al.

CURRENT OPINION IN IMMUNOLOGY (2010)

Add to Collection

Article Immunology

Hematopoietic progenitor cells and interleukin-stimulated endothelium: expansion and differentiation of myeloid precursors

Anja Moldenhauer et al.

BMC IMMUNOLOGY (2008)

Add to Collection

Article Dermatology

Chemokines: Key players in innate and adaptive immunity

C Esche et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2005)

Add to Collection

Review Cell Biology

Expression and function of chemokines during viral infections: from molecular mechanisms to in vivo function

J Melchjorsen et al.

JOURNAL OF LEUKOCYTE BIOLOGY (2003)

Add to Collection

Review Immunology

Viral mimicry of cytokines, chemokines and their receptors

A Alcami

NATURE REVIEWS IMMUNOLOGY (2003)

Add to Collection

Article Immunology

IL-7 enhances the survival and maintains the size of naive T cells

JC Rathmell et al.

JOURNAL OF IMMUNOLOGY (2001)

Add to Collection

Review Microbiology

Molecular pathways in virus-induced cytokine production

TH Mogensen et al.

MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.